olfactory receptor family 52 subfamily H member 1Genealiases: OR11-41 · OR11-45
Q-omics provides the consensus-scored OR52H1 profile across patient tissues and cancer cell-line models. OR52H1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OR52H1 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, OR52H1 RNA expression shows 13,290 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, LUSC, and LSCC as cancer lineages where OR52H1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52H1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52H1 survival associations across molecular data types. OR52H1 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52H1 RNA expression–survival associations across cancer types. High OR52H1 expression shows unfavorable associations in KICH, THCA, UVM, LGG and LIHC, but favorable associations in MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OR52H1 RNA expression.
This table summarizes OR52H1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR52H1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52H1 shows lower tumor expression in LUSC, ESCA, BRCA, LUAD and THCA and higher tumor expression in KIRC. The LUSC box plot shows higher OR52H1 RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .001).
This table shows molecular features associated with OR52H1 in patient tissues and cancer cell lines. In patient samples, OR52H1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52H1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
